Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

179
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
179
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

237
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
237
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.6K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

570
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
570
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

187
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
187
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

68
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
68

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consolidation of Painted Plasters in Hypogean Environments: Comparative Performance of Inorganic Calcium-Based Products Under High-Humidity and Water-Saturated Conditions.

Nanomaterials (Basel, Switzerland)·2026
Same author

TabularQual: A spreadsheet-based format for annotating and curating logical models in SBML-qual.

bioRxiv : the preprint server for biology·2026
Same author

Automated segmentation of hepatic vessels and lobules in whole-slide images using U-net models.

Frontiers in bioinformatics·2026
Same author

A Physiologically Based Pharmacokinetic and Pharmacodynamic (PBPK/PD) Model of Dapagliflozin in Type 2 Diabetes Mellitus: The Effect of Dosing, Hepatorenal Impairment, and Food.

Pharmaceutics·2026
Same author

From FAIR to CURE: guidelines for computational models of biological systems.

NPJ systems biology and applications·2026
Same author

Visuo-Vestibular Virtual Reality-Based Training for People with Stroke: A Feasibility Study.

Healthcare (Basel, Switzerland)·2026

Related Experiment Video

Updated: Dec 2, 2025

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.7K

PK-DB: pharmacokinetics database for individualized and stratified computational modeling.

Jan Grzegorzewski1, Janosch Brandhorst1, Kathleen Green2

  • 1Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, Berlin 10115, Germany.

Nucleic Acids Research
|November 5, 2020
PubMed
Summary

PK-DB is a new open database for accessing pharmacokinetics data from clinical trials. It provides curated information and tools to facilitate meta-analysis and computational modeling for personalized medicine.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.0K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Related Experiment Videos

Last Updated: Dec 2, 2025

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.7K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.0K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.9K

Area of Science:

  • Pharmacology
  • Bioinformatics
  • Data Science

Background:

  • Pharmacokinetics (PK) data is crucial for drug development and personalized medicine.
  • Existing PK data is fragmented and difficult to access due to the lack of open databases.
  • Meta-analysis and computational modeling require integrated, curated PK datasets.

Purpose of the Study:

  • To introduce PK-DB, an open-access database for pharmacokinetics information from clinical trials.
  • To provide a centralized platform for accessing curated PK data and associated metadata.
  • To support advanced computational modeling and meta-analysis of PK studies.

Main Methods:

  • Development of PK-DB, an open database with a web interface and REST API.
  • Curation of data including patient characteristics, interventions, PK parameters, and time-courses.
  • Implementation of features for error representation, unit normalization, ontology annotation, and data validation.
  • Development of a collaborative data curation workflow.

Main Results:

  • PK-DB offers comprehensive, curated pharmacokinetics data from clinical trials.
  • The database includes detailed information on patient cohorts, interventions, PK parameters, and time-courses.
  • Features like error representation, unit normalization, and ontology annotation enhance data usability.
  • PK-DB enables computational access via a REST API and human access via a web interface.

Conclusions:

  • PK-DB addresses the need for accessible, curated pharmacokinetics data.
  • The database facilitates meta-analysis and integration with computational models (PBPK, PK/PD, pop PK).
  • PK-DB supports individualized and stratified computational modeling for precision medicine.